Tissue polypeptide specific antigen and cancer antigen-15.3 as predictive biomarkers for metastasis in breast cancer
DOI:
https://doi.org/10.18203/issn.2454-2156.IntJSciRep20260775Keywords:
Breast cancer, Metastasis, Tissue polypeptide specific antigen, Cancer antigen-15.3Abstract
Background: The management of metastatic breast cancer patients reflects the heterogeneous nature of the disease. Distant metastasis of breast cancer is the main reason for the increasing mortality of breast cancer patients due to failure of breast cancer treatment. This study aimed at determining the association between levels of tissue polypeptide-specific antigen (TPS) compared with cancer antigen-15.3 (CA-15.3) as biomarkers for metastasis in breast cancers.
Methods: This is a cross-sectional study involving one-hundred and fifty (150) female participants who presented with histologically confirmed new cases of breast cancer at the Oncology Clinic of Lagos State University Teaching Hospital Ikeja. Blood samples were collected and run using enzyme-linked immunosorbent assay (ELISA), for TPS and CA-15.3. Data were analyzed using statistical package for the social sciences (SPSS) version 26.0 (Inc., Chicago, Ill). The comparison of median TPS and CA-15.3 between two groups was evaluated using the Mann-Whitney U test. Statistical significance was considered when the p value was ≤0.05.
Results: The most represented age group was 50 to 59 years (36.6%) with overall mean age, age and at diagnosis of 49.21±10.1 years, and 48.76±10.1 years respectively. There was statistically significant increase in CA-15.3 with increasing clinical stage of the participants (p<0.001). However, no significant relationship was noted between median TPS and all breast cancer related characteristics assessed (p>0.05). The AUC for CA-15.3 and TPS were 0.679 (95% CI=0.593-0.766) and 0.524 (95% CI=0.430-0.618) respectively.
Conclusions: CA-15.3 has a better diagnostic ability for predicting distant metastasis in breast cancer.
Metrics
References
Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. Cancer J Clin. 2021;71(3):209-49. DOI: https://doi.org/10.3322/caac.21660
Huang J, Chan PS, Lok V, Chen X, Ding H, Jin Y, et al. Global incidence and mortality of breast cancer: a trend analysis. Aging. 2021;13(4):5748-803. DOI: https://doi.org/10.18632/aging.202502
Arzanova E, Mayrovitz HN. The Epidemiology of Breast Cancer. In: Mayrovitz HN, editor. Breast Cancer. Brisbane (AU). Exon Publications. 2022. DOI: https://doi.org/10.36255/exon-publications-breast-cancer-epidemiology
Park M, Kim D, Ko S, Kim A, Mo K, Yoon H. Breast Cancer Metastasis: Mechanisms and Therapeutic Implications. Int J Mol Sci. 2022;23(12):6806. DOI: https://doi.org/10.3390/ijms23126806
Yang H, Wang R, Zeng F, Zhao J, Peng S, Ma Y, et al. Impact of molecular subtypes on metastatic behavior and overall survival in patients with metastatic breast cancer: A single center study combined with a large cohort study based on the Surveillance, Epidemiology and End Results database. Oncology Letters. 2020;20(4):1. DOI: https://doi.org/10.3892/ol.2020.11948
Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, et al. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018;1;5(2):77-106. DOI: https://doi.org/10.1016/j.gendis.2018.05.001
Zhang Y, Zhao J, Wang Y, Cai W, Zhang X, Li K, et al. Changes of Tumor Markers in Patients with Breast Cancer during Postoperative Adjuvant Chemotherapy. Dis Markers. 2022;19:7739777. DOI: https://doi.org/10.1155/2022/7739777
Fu Y, Li H. Assessing Clinical Significance of Serum CA15-3 and Carcinoembryonic Antigen (CEA) Levels in Breast Cancer Patients: A Meta-Analysis. Med Sci Monit Int Med J Exp Clin Res. 2016;6;22:3154-62. DOI: https://doi.org/10.12659/MSM.896563
Nanjundeswaraswamy TS, Divakar S. Determination of Sample size and Sampling Methods in Applied Research. Proc Eng Sci. 2021;3(1):25-32. DOI: https://doi.org/10.24874/PES03.01.003
Balekouzou A, Yin P, Pamatika CM, Bishwajit G, Nambei SW, Djeintote M, et al. Epidemiology of breast cancer: retrospective study in the Central African Republic. BMC Public Health. 2016;7;16(1):1230. DOI: https://doi.org/10.1186/s12889-016-3863-6
Abdus-salam Abbas A, Ogunnorin Babatunde Olutoye, Adenipekun AdeniyiA,, Olabumuyi Adeniyi Adedayo, Olabumuyi Percentage body fat in breast cancer patients at the University College Hospital, Ibadan: a case-control study. Niger J Med. 2019;237-47. DOI: https://doi.org/10.4103/1115-2613.278592
Fregene A, Newman LA. Breast cancer in sub-Saharan Africa: how does it relate to breast cancer in African-American women? Cancer. 2005;103(8):1540-50. DOI: https://doi.org/10.1002/cncr.20978
Akarolo-Anthony SN, Ogundiran TO, Adebamowo CA. Emerging breast cancer epidemic: evidence from Africa. Breast Cancer Res. 2010;12:S8. DOI: https://doi.org/10.1186/bcr2737
Ogundiran TO, Huo D, Adenipekun A, Campbell O, Oyesegun R, Akang E, et al. Case-control study of body size and breast cancer risk in Nigerian women. Am J Epidemiol. 2010;172(6):682-90. DOI: https://doi.org/10.1093/aje/kwq180
Adeniji AA, Dawodu OO, Habeebu MY, Oyekan AO, Bashir MA, Martin MG, et al. Distribution of breast cancer subtypes among Nigerian women and correlation to the risk factors and clinicopathological characteristics. World J Oncol. 2020;11(4):165-72. DOI: https://doi.org/10.14740/wjon1303
Steponavičienė L, Gudavičienė D, Meškauskas R. Rare types of breast carcinoma. Acta Med Litu. 2012;19(2):81-91. DOI: https://doi.org/10.6001/actamedica.v19i2.2314
Ntekim AI. Survival pattern of rare histological types of breast cancer in a Nigerian institution. Pan Afr Med J. 2019;34:114. DOI: https://doi.org/10.11604/pamj.2019.34.114.16925
Popoola A, Ogunleye O, Ibrahim N. Five-year survival of patients with breast cancer at the Lagos State University Teaching Hospital, Nigeria. Online J Med Med Sci Res. 2012;1(2):24-31.
Ibrahim NA, Oludara MA. Socio-demographic factors and reasons associated with delay in breast cancer presentation: a study in Nigerian women. Breast. 2012;21(3):416-8. DOI: https://doi.org/10.1016/j.breast.2012.02.006
Dairo MD, Adamu DB, Onimode YA, et al. Characteristics and determinants of patients discontinuation of breast cancer follow-up care at the Radiation Oncology Department, University College Hospital, Ibadan, Nigeria. Int J Breast Cancer. 2018;2018:1597964. DOI: https://doi.org/10.1155/2018/1597964
Oguntola A, Agodirin S, Adeoti M. Bilateral breast cancer: experience in a poor resource Black African setting. East Cent Afr J Surg. 2010;15(1):28-34.
Popoola A, Ibrahim N, Omodele F. Pattern of spread of breast cancer among patients attending cancer unit of Lagos State University Teaching Hospital. Asian J Med Sci. 2012;4(3):89-94.
Anyanwu SN. Survival following treatment of primary breast cancer in eastern Nigeria. East Afr Med J. 2000;77(10):539-43.
Ali-Gombe M, Muhammad IM, Ayorinde F, Ntekim A, Babatunde CO. Pattern of survival of breast cancer patients in a tertiary hospital in south west Nigeria. Ecancermedicalscience. 2021;15:1192. DOI: https://doi.org/10.3332/ecancer.2021.1192
Elumelu TN, Adenipekun AA, Abdus-salam AA, et al. Pattern of breast cancer metastasis at the radiotherapy clinic, Ibadan – a ten-year review. J Am Sci. 2011;7(7):906-12.
Wu SG, He ZY, Zhou J, Sun JY, Li FY, Lin Q, et al. Serum levels of CEA and CA15-3 in different molecular subtypes and prognostic value in Chinese breast cancer. Breast. 2014;23(1):88-93. DOI: https://doi.org/10.1016/j.breast.2013.11.003
Gaughran G, Aggarwal N, Shadbolt B, Stuart-Harris R. The utility of the tumor markers CA15-3, CEA, CA-125 and CA19.9 in metastatic breast cancer. Breast Cancer Manag. 2020;9(4). DOI: https://doi.org/10.2217/bmt-2020-0015
Goorts B, van Nijnatten TJA, de Munck L, Moossdorff M, Heuts EM, de Boer M, et al. Clinical tumor stage is the most important predictor of pathological complete response rate after neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat. 2017;7:3. DOI: https://doi.org/10.1007/s10549-017-4155-2
Xie S, Ding X, Mo W, Chen J. Serum tissue polypeptide-specific antigen is an independent predictor in breast cancer. Acta Histochem. 2014;116(2):372-6. DOI: https://doi.org/10.1016/j.acthis.2013.09.001
Zhao W, Li X, Wang W, Chen B, Wang L, Zhang N, et al. Association of preoperative serum levels of CEA and CA15-3 with molecular subtypes of breast cancer. Dis Markers. 2021;2021:5529106. DOI: https://doi.org/10.1155/2021/5529106
Sliwowska I, Kopczyński Z, Grodecka-Gazdecka S. Diagnostic value of measuring serum CA 15-3, TPA, and TPS in women with breast cancer. Postepy Hig Med Dosw (Online). 2006;60:295-9.
Downloads
Published
How to Cite
Issue
Section
